

DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

L4 (transplant\$ or graft\$)same (alkylating or bulsulfan)same (after or post) 4 L4

DB=PGPB, USPT; PLUR=YES; OP=ADJ

L3 (transplant\$ or graft\$)same (alkylating or bulsulfan)same (after or post) 56 L3

L2 L1 and (transplant\$ or graft\$) and (alkylating or busulfan) 8 **L2**

L1 larsen.in. 3247 L1

END OF SEARCH HISTORY

Help

```
Set Items Description
--- -----
? set hi ;set hi
HIGHLIGHT set on as ''
HIGHLIGHT set on as ''
? begin 5,73,15,399
    21nov05 08:31:25 User208760 Session D2658.2
        $0.00    0.102 DialUnits File410
        $0.00  Estimated cost File410
        $0.02   TELNET
        $0.02  Estimated cost this search
        $0.54  Estimated total session cost  0.250 DialUnits
```

SYSTEM:OS - DIALOG OneSearch

```
File 5:Biosis Previews(R) 1969-2005/Nov W2
(c) 2005 BIOSIS
File 73:EMBASE 1974-2005/Nov 21
(c) 2005 Elsevier Science B.V.
File 15:ABI/Inform(R) 1971-2005/Nov 19
(c) 2005 ProQuest Info&Learning
File 399:CA SEARCH(R) 1967-2005/UD=14322
(c) 2005 American Chemical Society
```

*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.

```
Set Items Description
--- -----
? e au=larsen christian ?

Ref   Items Index-term
E1      6 AU=LARSEN CHRISTEN P
E2      5 AU=LARSEN CHRISTIAN
E3      0 *AU=LARSEN CHRISTIAN ?
E4      7 AU=LARSEN CHRISTIAN G
E5      1 AU=LARSEN CHRISTIAN GRONBHOJ
E6      15 AU=LARSEN CHRISTIAN GRONHOJ
E7      1 AU=LARSEN CHRISTIAN J
E8      1 AU=LARSEN CHRISTIAN JACQUES
E9      1 AU=LARSEN CHRISTIAN KLEIN
E10     61 AU=LARSEN CHRISTIAN P
E11     3 AU=LARSEN CHRISTIAN RIFBJERG
E12     35 AU=LARSEN CHRISTIAN-JACQUES
```

Enter P or PAGE for more

```
? s e10
    S1      61 AU='LARSEN CHRISTIAN P'
? s s1 and (alkylating or bulsulfan?)
    61 S1
    29292 ALKYLATING
    17 BULSULFAN?
    S2      0 S1 AND (ALKYLATING OR BULSULFAN?)
? s (alkylating or bulsulfan?)(20n)(transplant? or graft?)(20n)post or afer)
>>>Unmatched parentheses
? s (alkylating or bulsulfan?)(20n)(transplant? or graft?)(20n)(post? or afer)
>>>File 5 processing for POST? stopped at POSTDETRAINING
>>>File 73 processing for POST? stopped at POSTDAMAGE
>>>File 15 processing for POST? stopped at POSTOUTBREAK
>>>File 399 processing for POST? stopped at POSTOXIDATION
    29292 ALKYLATING
    17 BULSULFAN?
    1259757 TRANSPLANT?
    430248 GRAFT?
    904039 POST?
    1811 AFER
    S3      15 (ALKYLATING OR BULSULFAN?)(20N)(TRANSPLANT? OR
                GRAFT?)(20N)(POST? OR AFER)
? rd s3
```

...completed examining records
S4 9 RD S3 (unique items)
? t s4/3/all

4/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0014998922 BIOSIS NO.: 200400369711
Autologous stem cell **transplantation** using modified TAM or combination of triple-**alkylating** agents conditioning regimens as one of the **post**-remission treatments in patients with adult acute myeloid leukemia in first complete remission
AUTHOR: Kim H J; Min W S (Reprint); Eom K S; Park S J; Park Y H; Kim D W; Lee J W; Park C W; Kim C C
AUTHOR ADDRESS: Coll MedCatholic Hemopoiet Stem Cell Transplantat CtrDept Internal Med, Div Hematol, Catholic Univ Korea, Seoul, 150713, South Korea **South Korea
AUTHOR E-MAIL ADDRESS: wsmin@catholic.ac.kr
JOURNAL: Bone Marrow Transplantation 34 (3): p215-220 August 2004 2004
MEDIUM: print
ISSN: 0268-3369 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0014780200 BIOSIS NO.: 200400146861
Myelodysplastic CD34+ clones can be detected by fluorescent in situ hybridization in the stem cell harvest of myeloma patients who develop treatment-related myelodysplastic syndrome following autologous transplantation.
AUTHOR: Thertulien Raymond (Reprint); Ojha Rohit (Reprint); Zangari Maurizio (Reprint); Fassas Athanasios (Reprint); Anaissie Elias J (Reprint); Lee Choon-Kee (Reprint); vanRhee Frits (Reprint); Barlogie Bart (Reprint); Tricot Guido J (Reprint)
AUTHOR ADDRESS: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 776, Little Rock, AR, USA**USA
JOURNAL: Blood 102 (11): p424a November 16, 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

4/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0014039869 BIOSIS NO.: 200200633380
Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling
AUTHOR: Anserini P (Reprint); Chiodi S; Spinelli S; Costa M; Conte N; Copello F; Bacigalupo A
AUTHOR ADDRESS: Centro Infertilita, Dipartimento di Ostetricia e Ginecologia, Universita di Genova, Ospedale San Martino, Pad 1, Largo Benzi, 16132, Genova, Italy, Italy**Italy
JOURNAL: Bone Marrow Transplantation 30 (7): p447-451 October 2002 2002

2002

MEDIUM: print

ISSN: 0268-3369

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

4/3/4 (Item 4 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0013133644 BIOSIS NO.: 200100305483

Successful treatment of scleromyxedema with autologous peripheral blood
stem cell transplantation

AUTHOR: Hogan William J (Reprint); Lacy Martha Q (Reprint); Schroeter
Arnold L; Litzow Mark R (Reprint); Gertz Morie A (Reprint)

AUTHOR ADDRESS: Division of Hematology, Mayo Medical Center, Rochester, MN,
USA**USA

JOURNAL: Blood 96 (11 Part 2): p370b November 16, 2000 2000

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of
Hematology San Francisco, California, USA December 01-05, 2000; 20001201

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

4/3/5 (Item 5 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0011994025 BIOSIS NO.: 199900253685

Administration and pharmacokinetics of high-dose cyclophosphamide with
hemodialysis support for allogeneic bone marrow transplantation in acute
leukemia and end-stage renal disease

AUTHOR: Perry J J (Reprint); Fleming R A; Rocco M V; Petros W P; Bleyer A J
; Radford J E Jr; Powell B L; Hurd D D

AUTHOR ADDRESS: Section of Hematology/Oncology, Department of Internal
Medicine, Wake Forest University School of Medicine, Medical Center
Boulevard, Winston-Salem, NC, 27157, USA**USA

JOURNAL: Bone Marrow Transplantation 23 (8): p839-842 April 2, 1999 1999

MEDIUM: print

ISSN: 0268-3369

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

4/3/6 (Item 6 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0011688543 BIOSIS NO.: 199800482790

The role of thioguanine in autologous bone marrow transplantation for acute
leukemia

AUTHOR: Nagler Arnon (Reprint); Finlander Rosales; Or Reuven; Naparstek
Elizabeth; Varadi Gabor; Slavin Shimon

AUTHOR ADDRESS: Dep. Bone Marrow Transplant., Hadassah Univ. Hosp.,
Jerusalem, Israel**Israel

JOURNAL: Leukemia Research 22 (11): p991-995 Nov., 1998 1998

MEDIUM: print

ISSN: 0145-2126

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

4/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0010003328 BIOSIS NO.: 199598471161
Relapse of multiple myeloma after autologous transplantation: Survival
after salvage therapy
AUTHOR: Tricot G (Reprint); Jagannath S; Vesole D H; Crowley J; Barlogie B
AUTHOR ADDRESS: Div. Hematol./Oncol., Univ. Arkansas Med. Sci., 4301 West
Markham, Slot 508, Little Rock, AR 72205, USA**USA
JOURNAL: Bone Marrow Transplantation 16 (1): p7-11 1995 1995
ISSN: 0268-3369
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/8 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2005 Elsevier Science B.V. All rts. reserv.

06664232 EMBASE No: 1996329113
Preceding standard therapy is the likely cause of MDS after
autotransplants for multiple myeloma
Govindarajan R.; Jagannath S.; Flick J.T.; Vesole D.H.; Sawyer J.;
Barlogie B.; Tricot G.
Division of Hematology/Oncology, Univ. Arkansas for Medical Sciences,
4301 West Markham, Slot 508, Little Rock, AR 72205 United States
British Journal of Haematology (BR. J. HAEMATOL.) (United Kingdom)
1996, 95/2 (349-353)
CODEN: BJHEA ISSN: 0007-1048
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

4/3/9 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2005 Elsevier Science B.V. All rts. reserv.

02738602 EMBASE No: 1984057561
Malignant lesions in rheumatoid arthritis; the influence of treatment
with cyclophosphamide
Baltus J.A.M.; Boersma J.W.; Vandenbroucke J.P.
Afd. Reumatologie, Gemeente Ziekenhuis, Arnhem Netherlands
Nederlands Tijdschrift voor Geneeskunde (NED. TIJDSCHR. GENEESKD.) (Netherlands)
1984, 128/5 (205-209)
CODEN: NETJA
DOCUMENT TYPE: Journal
LANGUAGE: DUTCH SUMMARY LANGUAGE: ENGLISH
? t s4/kwic/all
>>>KWIC option is not available in file(s): 399

4/KWIC/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

Autologous stem cell transplantation using modified TAM or
combination of triple-alkylating agents conditioning regimens as
one of the post-remission treatments in patients with adult acute
myeloid leukemia in first complete remission

4/KWIC/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

...ABSTRACT: to the clinical presentation of t-MDS. Our data support the hypothesis that conventional pre-transplant alkylating chemotherapy is the major culprit for the development of post-transplant MDS, which may be accentuated by the stress of hematopoietic recovery. Our findings suggest that the risk of ***post*** - transplant MDS may be decreased by limiting pretransplant induction treatment to <6 mos and limiting exposure...

4/KWIC/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

...ABSTRACT: of patients, whereas it was consistently severely impaired in patients who received irradiation or two ***alkylating*** agents. Following CY, spermatogenesis recovery was observed in 60% of patients tested 1 year post transplant and it was accomplished within the third year in 80% of cases. Following CY+TBI/TAI recovery of spermatogenesis never occurred before the 4th year post transplant and was demonstrated as late as 9 years in one patient who was azoospermic 1...

4/KWIC/4 (Item 4 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

...ABSTRACT: Neither patient has demonstrated clinical or laboratory evidence of relapse at 19 and 8 months post transplant respectively. Conclusion We believe that autologous hematopoietic progenitor cell transplantation should be considered in patients with scleromyxedema. It is prudent to consider stem-cell harvest before prolonged exposure to melphalan, because alkylating agents can affect the quantity and quality of stem-cell harvests.

4/KWIC/5 (Item 5 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

...ABSTRACT: and its metabolites. Pharmacokinetic analyses indicated that the elimination of high-dose CY and its alkylating metabolites is impaired in ESRD but is cleared with hemodialysis. The patient's early post-transplant course was uncomplicated, and WBC and platelet engraftment occurred by day +22. Bone marrow examination...

4/KWIC/6 (Item 6 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

ABSTRACT: Post-transplant leukemic relapse remains the major problem following autologous bone marrow ***transplantation*** (ABMT). One possible approach to reducing the relapse rate is to intensify pretransplant conditioning. Thiotapec (TTP) is an ***alkylating*** agent that has been used mainly in breast and ovarian cancer with 20-50% responses...

4/KWIC/7 (Item 7 from file: 5)
DIALOG(R)File 5:(c) 2005 BIOSIS. All rts. reserv.

...ABSTRACT: lack of progress with standard chemotherapy and the presence of a dose response effect for alkylating agents, autotransplantation is performed with increasing frequency for multiple myeloma (MM). However, sustained relapse-free...

...patients who had relapsed following autotransplantation, in order to evaluate the efficacy of further therapy. ***Post*** - ***transplant*** salvage treatment consisted of either standard dose therapy (53) or transplantation with an intensive preparative...

4/KWIC/8 (Item 1 from file: 73)

DIALOG(R)File 73:(c) 2005 Elsevier Science B.V. All rts. reserv.

...group 2) with more prolonged conventional therapy ($P = 0.0001$). All seven patients developing MDS **post-transplantation** belonged to group 2 ($P = 0.02$); the median durations from initial therapy and first **transplant** were 66 months (range 38-86) and 24 months (range 9-39), respectively. Our findings provide evidence that prolonged standard-dose **alkylating agent** therapy prior to transplantation, rather than autotransplant-supported myeloablative treatment, is associated with development...

4/KWIC/9 (Item 2 from file: 73)

DIALOG(R)File 73:(c) 2005 Elsevier Science B.V. All rts. reserv.

...of the malignant tumours that have been described in connection with immunosuppression. This category included ***post*** - ***transplantation*** patients and patients with other indications for cytotoxic therapy. The ***alkylating*** agents emerged as a particularly pronounced risk factor. The same holds true of RA, and...
?